• Share
  • Email
  • Embed
  • Like
  • Save
  • Private Content
 Glaxo-smith-kline-presentation.
 

Glaxo-smith-kline-presentation.

on

  • 6,787 views

 

Statistics

Views

Total Views
6,787
Views on SlideShare
6,787
Embed Views
0

Actions

Likes
1
Downloads
326
Comments
0

0 Embeds 0

No embeds

Accessibility

Categories

Upload Details

Uploaded via as Microsoft PowerPoint

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

     Glaxo-smith-kline-presentation. Glaxo-smith-kline-presentation. Presentation Transcript

    • Glaxo Smith Kline
    • GSK’S Introduction
      GlaxoSmithKline often abbreviated to GSK, is a global
      pharmaceutical, biologics, vaccines and consumer
      healthcare company headquartered in London, United
      Kingdom.
    • GSK’S Introduction
      It is world’s third largest pharmaceutical company measured by revenues ( after Johnson and Johnson and Pfizer.
      It has a portfolio of products for major disease areas including asthma, cancer, virus control, infections, mental health, diabetes and digestive conditions.
    • History
      • GlaxoSmithKline plc is a public limited company incorporated on 6th December 1999 under English law. Its shares are listed on the London Stock Exchange and the New York Stock Exchange.
      • On 27th December 2000 the company acquired Glaxo Wellcome plc and SmithKline Beecham plc, both English public limited companies, by way of a scheme of arrangement for the merger of the two companies.
    • History
      GSK and its subsidiary and associated undertakings constitute a major global healthcare group engaged in the creation, discovery, development, manufacture and marketing of pharmaceutical and consumer health-related products.
      GSK has its corporate head office in London and has its US headquarters in Research Triangle Park, North Carolina, with operations in some 120 countries, and products sold in over
      150 countries.
    • Chairman:
      Sir Christopher Gent
      Chief Executive Officer:
      Andrew Witty
    • GSK’s Mission
      GSK MISSION
      GROW
      MISSION
      SIMPLYFY
      DELIVER
    • GSK’S Mission
      • Grow a diversified global business – We are diversifying our business to create a more balanced product portfolio and move away from a reliance on traditional ‘white pill/western markets’. We are investing in key growth areas such as Emerging Markets, Japan, Vaccines and our Consumer Healthcare business.
      .
    • GSK’S Mission
      • Deliver more products of value – We aim to sustain an
      industry-leading pipeline of products, ensuring that they
      demonstrate value for healthcare providers. Our R&D
      strategy is built around focusing on the best science,
      diversifying through externalisation of research, and
      improving the returns on investment.
    • GSK’S Mission
      • Simplify the operating model – GSK is a large and complex organisation. We are transforming our operating model to reduce complexities, improve efficiency and reduce costs
    • Products
      Prescription medicines
      Vaccines
      Consumer Healthcare
    • PRESCRIPTION MEDICINES
    • ALLI-WEIGHT LOSS DRUG
    • AVANDIA-DIABETIS CONTROL
    • ROTAVIRUS VACCINE ROTARIX
    • VACCINE FOR MEASLES
    • CONSUMER HEALTHCARE PRODUCTS
    • CONSUMER HEALTHCARE PRODUCTS
    • Two other companies
      Stiefel, a GSK company— A Global Leader in Dermatology
      ViiV Healthcare —
      a global specialist HIV company established by GlaxoSmithKline and Pfizer to deliver advances in treatment and care for people
    • STIEFEL-A GSK COMPANY
    • VIIV- HEALTHCARE COMPANY
    • Turnover ( in billion pounds)
      2009 28.4
      2008 24.4
      2007 22.7
      2006 23.2
      2005 21.7
    • World market by geographic region
      value(billion pounds) % of total
      USA 187 40
      Europe 131 28
      France 25 5
      Germany 24 5
      Italy 16 3
      UK 12 3
      Rest of World 150 32
      Emerging markets 66 14
      Asia Pacific 20 4
      Japan 50 11
      Canada 11 2
    • Regional analysis
      (2009) (2008) cer% pnd%
      USA 9,180 8,894 (13) 3
      Europe 7,681 6,483 9 18
      Emerging Markets 2,973 2,290 20 30
      Asia Pacific/Japan 2,700 1,918 16 41
      Other trading‡ 1,180 796 31 48
      23,714 20,381 2 16
    • CER% represents growth at constant exchange rates.
      Pound % growth at actual exchange rates.
    • Consumer Healthcare turnover(million pounds)
      (2009) (2008) cer% pound %
      Over the counter 2,319 1935 8 20
      Medicines
      Oral healthcare 1484 1240 7 20
      Nutritional healthcare 851 796 3 7
    • Sales Trend
    • Five countries chosen
      • USA
      • JAPAN
      • GERMANY
      • SWITZERLAND
      • UK
    • COMPETITORS IN USA
      NAME OF THE COMPANY
      Johnson & Johnson
      Abbott Laboratories
      Merck & Co.
      Eli lilly
      Bristol-Myers Squibb
      TOTAL REVENUE(IN USD BILLIONS )
      61.90
      30.76
      27.43
      21.84
      18.81
    • JOHNSON &JOHNSON
    • ABBOT LABORATARIES
    • MERCK &CO.
    • ELI LILLY
    • BRISTOL-MYERS SQUIBB
    • COMPETITORS IN JAPAN
      NAME OF THE COUNTRY
      TAKEDAPHARMACEUTICAL.
      ASTELLAS PHARMA
      DAIICHI SANKYO 9
      EISAI
      CHUGAI PHARMACEUTICAL .
      TOTAL REVENUE
      (IN USD BILLIONS)
      15.6
      10.7
      9
      5.5
      2.0
    • TAKEDA PHARMACEUTICALS
    • ASTELLAS PHARMA
    • DAIICHI SANKYO
    • EISAI
    • CHUGAI PHARMACEUTICALS
    • COMPETITORS IN GERMANY
      NAME OF THE COUNTRY
      BAYER
      BOEHRINGER INGELHEIM
      MERCK kGaA
      TOTAL REVENUE
      (IN USD BILLIONS)
      22.3
      16.9
      5.17
    • BAYER
    • BOEHRINGER INGELHEIM
    • MERCK KGAA
    • COMPETITORS IN SWITZERLAND
      NAME OF THE COUNTRY
      HOFFMAN LA ROCHE
      NOVARTIS
      NYCOMED
      TOTAL REVENUE
      (IN USD BILLIONS)
      47.35
      44.27
      4.26
    • HOFFMAN LA ROCHE
    • NOVARTIS
    • NYCOMED
    • COMPETITORS IN UK
      NAMEOF THE COMPANY
      TOTAL REVENUE
      (IN USD BILLIONS)
      45.83
      32.81
      GlaxoSmithKline
      AstraZeneca
    • ASTRA ZENECA
    • SUBMITTED BY:
      ISHDEEP SINGH
      M100700019